CLINICAL TRIALS PROFILE FOR OXFENDAZOLE
✉ Email this page to a colleague
Clinical Trials for Oxfendazole
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01584362 ↗ | Single Ascending Dose Safety Study of Oxfendazole | Withdrawn | School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos | Phase 1 | This research is being done to learn about the safety in humans of a medicine that is already used in cows and pigs to treat worms. The medicine may be useful for people who have these or other worms. The medicine will be studied first in healthy people, who will be given a very small amount of the medicine once. If the smallest amount of medicine is found to be safe, a slightly higher amount will be given to a new group of volunteers. The highest amount that will be tested is similar to the amount given to animals. If the medicine can be given safely to healthy people in the planned amounts, a later study will be done in people who have worms to see if the medicine kills the worms. |
| NCT01584362 ↗ | Single Ascending Dose Safety Study of Oxfendazole | Withdrawn | Universidad Peruana Cayetano Heredia | Phase 1 | This research is being done to learn about the safety in humans of a medicine that is already used in cows and pigs to treat worms. The medicine may be useful for people who have these or other worms. The medicine will be studied first in healthy people, who will be given a very small amount of the medicine once. If the smallest amount of medicine is found to be safe, a slightly higher amount will be given to a new group of volunteers. The highest amount that will be tested is similar to the amount given to animals. If the medicine can be given safely to healthy people in the planned amounts, a later study will be done in people who have worms to see if the medicine kills the worms. |
| NCT01584362 ↗ | Single Ascending Dose Safety Study of Oxfendazole | Withdrawn | Johns Hopkins Bloomberg School of Public Health | Phase 1 | This research is being done to learn about the safety in humans of a medicine that is already used in cows and pigs to treat worms. The medicine may be useful for people who have these or other worms. The medicine will be studied first in healthy people, who will be given a very small amount of the medicine once. If the smallest amount of medicine is found to be safe, a slightly higher amount will be given to a new group of volunteers. The highest amount that will be tested is similar to the amount given to animals. If the medicine can be given safely to healthy people in the planned amounts, a later study will be done in people who have worms to see if the medicine kills the worms. |
| NCT02234570 ↗ | Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | The objectives of the Phase I study are to evaluate the safety and tolerance of increasing single oral doses of oxfendazole in healthy volunteers.The secondary objectives assess the pharmacokinetic profile of oxfendazole and assess the metabolism of oxfendazole. The description of agent used is single oral dose of an aqueous suspension of oxfendazole, a benzimidazole carbamate antiparasitic drug. Each new cohort will be dosed only after the two week safety data for the preceding group have been reviewed. If a clinically significant AE is observed, and if this event is drug-related the safety monitoring committee will be convened to determine whether the study should continue. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Oxfendazole
Condition Name
Clinical Trial Locations for Oxfendazole
Trials by Country
Clinical Trial Progress for Oxfendazole
Clinical Trial Phase
Clinical Trial Sponsors for Oxfendazole
Sponsor Name
